Clarity Pharmaceuticals (CU6) H2 2026 earnings summary

Executive summary

• Advanced two pivotal Phase III trials (AMPLIFY and CLARIFY) for SAR-bisPSMA, targeting US FDA approval and commercial launch in the blockbuster PSMA PET market.

• Achieved strong clinical data, with 64Cu-SAR-bisPSMA outperforming standard-of-care agents in lesion detection and management impact for prostate cancer.

• SECURE trial for 67Cu-SAR-bisPSMA in mCRPC showed promising efficacy and safety, with 31% of evaluable patients at 8 GBq dose achieving complete response or undetectable disease.

• Maintained robust financial position with $178.3 million in cash as of 30 June 2026, following a $203 million institutional placement.

• Expanded manufacturing and supply chain, securing agreements for copper-64 and copper-67 to support anticipated product launches.

Financial highlights

• Net loss for the year was $107.2 million, up from $64.3 million in 2025, driven by increased R&D and commercial-readiness expenses.

• Research and development expenses rose to $91.1 million, reflecting expanded clinical trial activity.

• Liquid assets increased to $178.3 million (2025: $84.1 million), with net assets at $186.1 million (2025: $90.2 million).

• No dividends declared or paid.

Outlook and guidance

• Anticipates FDA approval and commercial launch of 64Cu-SAR-bisPSMA in the US, with pivotal trial readouts expected soon.

• Plans to initiate a registrational Phase III trial for 64Cu-SARTATE in neuroendocrine tumours following positive Phase II data.

• Focused on expanding the pipeline with new theranostic agents, including SAR-bisFAP and SAR-HER2.